Document is current
Any future updates will be listed below
-
Authors
Martens, Fabrice M. A. C. https://orcid.org/0000-0002-0977-7276
Visseren, Frank L. J.
Westerink, Jan
Spee, Ruud F.
Saloua, El Messaoudi
Mosterd, Arend
Handoko, Louis M.
Leening, Maarten J. G.
Römer, Tjeerd J.
Slootweg, Andries
van Bon, Arianne C.
Hemels, Martin E. W.
- License Information
-
More Information
Article History
Accepted: 26 May 2025
First Online: 9 July 2025
Conflict of interest
: L.M. Handoko reports receiving consultancy/speaker fees from Novartis, Daiichi Sankyo, Boehringer Ingelheim, Vifor Pharma, AstraZeneca, Bayer, MSD and Abbott; all not related to this work. He received an educational grant from Novartis and Boehringer Ingelheim and investigator-initiated research grants from Vifor Pharma and Novo Nordisk. L.M. Handoko is supported by the Dutch Heart Foundation (2020T058) and Netherlands CardioVascular Re-search Initiative (CVON; 2020B008). M.J.G. Leening reports receiving consultancy/speaker fees from Sanofi, Novartis, Novo Nordisk, Daiichi Sankyo, and Boehringer Ingelheim. M.J.G. Leening reports receiving research funding from Novo Nordisk, Novartis, and Sanofi. Andries Slootweg reports receiving consultancy/speakers fees from Novartis, Daiichi Sankyo, and Novo Nordisk. M.E.W. Hemels reports receiving consultancy/speaker fees from Amgen, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Novo Nordisk, and Sanofi. F.M.A.C. Martens reports investigator-initiated research grants from Novartis, Amarin, Novo Nordisk, and EU IHI for the GOLDEN-study, from the Dutch Heart Foundation for the EUROASPIRE-study, and from ZE&GG and ZonMw for the 2‑DECIDE-study. All consultancy/speaker fees go to the SpeakerfeeBureau/Research BV of the Heart Centre Amsterdam UMC. F.L.J. Visseren, J. Westerink, R.F. Spee, E.M. Saloua, A. Mosterd, T.J. Römer, A. Slootweg and A.C. van Bon declare that they have no competing interests.
